- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about MNMD
Recent news which mentions MNMD
From InvestorPlace
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
From Benzinga
MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses
February 28, 2024
Tickers
MNMD
From Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
From Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
From Benzinga
Why Is ARB IOT (ARBB) Stock Up 230% Today?
February 13, 2024
From InvestorPlace
Why Is MindMed (MNMD) Stock Up 8% Today?
February 12, 2024
From InvestorPlace
Elon Musk Says, 'If Drugs Helped My Productivity I'd Take Them' — This Psychedelic Bio-Tech Company Hopes To Help Build That Future
February 05, 2024
Tickers
MNMD
From Benzinga
FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000
January 31, 2024
From Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
From Benzinga
From Benzinga
MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued
January 11, 2024
From Benzinga
Why Is Clearmind (CMND) Stock Up 40% Today?
January 10, 2024
From InvestorPlace
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
From Benzinga
Psychedelic Stock Gainers And Losers From January 1, 2024
January 01, 2024
From Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
December 27, 2023
From Benzinga
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
December 18, 2023
From Benzinga
MindMed’s stock boosted by positive data in trial of LSD as treatment for anxiety disorder
December 14, 2023
From MarketWatch
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
December 11, 2023
From Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
December 05, 2023
From Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
November 24, 2023
From Benzinga
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
November 23, 2023
From Benzinga
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
November 12, 2023
From Benzinga
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
November 06, 2023
From Benzinga
MindMed Q3 2023: Financials, Business Funded By 2026 If LSD Pipeline Milestones Achieved
November 03, 2023
Tickers
MNMD
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.